We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

4

Utipro® Plus Launched In France

We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.

Read more

Utipro® Plus Launched In Israel

We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections. Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017. Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)

Read more

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Read more

Let's meet in..

2018, Oct 09

CPhI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more